Cited by 172Protein Kinase Regulation and GTPase SignalingMechanisms of cancer metastasisCancer Mechanisms and Therapy

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Targeting SET/I2PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy

Open access

Switzer, C H, Cheng, R Y S, Vitek, T M, Christensen, D J, Wink, D A, Vitek, M P·2011·Oncogene

DOI 10.1038/onc.2010.622PMC PMC3107340

Open this paper in CoChat — free account

Abstract

The SET oncoprotein participates in cancer progression by affecting multiple cellular processes, inhibiting the tumor suppressor protein phosphatase 2A (PP2A), and inhibiting the metastasis suppressor nm23-H1. On the basis of these multiple activities, we hypothesized that targeted inhibition of SET would have multiple discrete and measurable effects on cancer cells. Here, the effects of inhibiting SET oncoprotein function on intracellular signaling and proliferation of human cancer cell lines was investigated. We observed the effects of COG112, a novel SET interacting peptide, on PP2A activity, Akt signaling, nm23-H1 activity and cellular migration/invasion in human U87 glioblastoma and MDA-MB-231 breast adenocarcinoma cancer cell lines. We found that COG112 interacted with SET protein and inhibited the association between SET and PP2A catalytic subunit (PP2A-c) and nm23-H1. The interaction between COG112 and SET caused PP2A phosphatase and nm23-H1 exonuclease activities to increase. COG112-mediated increases in PP2A activity resulted in the inhibition of Akt signaling and cellular proliferation. Additionally, COG112 inhibited SET association with Ras-related C(3) botulinum toxin substrate 1 (Rac1), leading to decreased cellular migration and invasion. COG112 treatment releases the SET-mediated inhibition of the tumor suppressor PP2A, as well as the metastasis suppressor nm23-H1. These results establish SET as a novel molecular target and that the inhibition of SET may have beneficial effects in cancer chemotherapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/onc.2010.622

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Rho Family GTPases Regulate p38 Mitogen-activated Protein Kinase through the Downstream Mediator Pak1
Zhang, S., Han, J., Sells, M. A., Chernoff, J., Knaus, U. G., Ulevitch, R. J., & Bokoch, G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.41.23934 · Cited by 726
CIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677
Tumor Suppressor NM23-H1 Is a Granzyme A-Activated DNase during CTL-Mediated Apoptosis, and the Nucleosome Assembly Protein SET Is Its Inhibitor
Fan, Z., Beresford, P. J., Oh, D. Y., Zhang, D., & Lieberman, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00150-8 · Cited by 541
Protein phosphatase 2A regulatory subunits and cancer
Eichhorn, P. J. A., Creyghton, M. P., & Bernards, R. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.05.005 · Cited by 513
Regulation of Histone Acetylation and Transcription by INHAT, a Human Cellular Complex Containing the Set Oncoprotein
Seo, S.-B., McNamara, P., Heo, S., Turner, A., Lane, W. S., & Chakravarti, D. (2001) · Cell · doi:10.1016/s0092-8674(01)00196-9 · Cited by 481
Reduced Nm23/Awd protein in tumour metastasis and aberrant Drosophila development
Rosengard, A. M., Krutzsch, H. C., Shearn, A., Biggs, J. R., Barker, E. A., Margulies, I., King, C. R., Liotta, L. A., & Steeg, P. S. (1989) · Nature · doi:10.1038/342177a0 · Cited by 481
The Myeloid Leukemia-associated Protein SET Is a Potent Inhibitor of Protein Phosphatase 2A
Li, M., Makkinje, A., & Damuni, Z. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.19.11059 · Cited by 479
Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene.
Lindern, M. V., van Baal, S., Wiegant, J. C. A. G., Raap, A. K., Hagemeijer, A., & Grosveld, G. C. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.8.3346 · Cited by 392
ErbB Receptor-induced Activation of Stat Transcription Factors Is Mediated by Src Tyrosine Kinases
Olayioye, M. A., Beuvink, I., Horsch, K., Daly, J. M., & Hynes, N. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.24.17209 · Cited by 373
Multiple pathways regulated by the tumor suppressor PP2A in transformation
Westermarck, J., & Hahn, W. C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.02.001 · Cited by 344

Flagged first, then by citations

Show all 50 references

Sorted by citations

Items 101–172 of 172

Trichloroethylene-induced downregulation of miR-199b-5p contributes to SET-mediated apoptosis in hepatocytes
Ren, X., Chen, Z., Ruan, J., Zhong, J., Rongxia, D., Liu, W., Huang, X., Yang, X., Liu, Y., & Liu, J. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09479-3 · Cited by 14
Phosphorylation of SET mediates apoptosis via P53 hyperactivation and NM23-H1 nuclear import
Wu, M., Yu, G., Yan, T., Ke, D., Wang, Q., Liu, R., Wang, J., Zhang, B., Chen, D., & Wang, X. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.04.022 · Cited by 14
Apolipoproteins as context-dependent regulators of lung inflammation
Figueroa, D. M., Gordon, E. M., Yao, X., & Levine, S. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813553-2.00013-0 · Cited by 15
Cyclin-dependent kinase 1-mediated phosphorylation of SET at serine 7 is essential for its oncogenic activity
Yin, L., Zeng, Y., Xiao, Y., Chen, Y., Shen, H., & Dong, J. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1621-2 · Cited by 14
p53 Function Is Compromised by Inhibitor 2 of Phosphatase 2A in Sonic Hedgehog Medulloblastoma
Wei, Y., Maximov, V. D., Morrissy, A. S., Taylor, M. D., Pallas, D. C., & Kenney, A. M. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0485 · Cited by 13
Thirty years of SET/TAF1β/I2PP2A: from the identification of the biological functions to its implications in cancer and Alzheimer’s disease
Mambro, A. D., & Esposito, M. T. (2022) · Bioscience Reports · doi:10.1042/bsr20221280 · Cited by 12
Novel secretome-to-transcriptome integrated or secreto-transcriptomic approach to reveal liquid biopsy biomarkers for predicting individualized prognosis of breast cancer patients
Ankney, J. A., Xie, L., Wrobel, J. A., Wang, L., & Chen, X. (2019) · BMC Medical Genomics · doi:10.1186/s12920-019-0530-7 · Cited by 13
Bi-Functional Peptides as a New Therapeutic Tool for Hepatocellular Carcinoma
Savier, É., Simón‐Gracia, L., Charlotte, F., Tufféry, P., Teesalu, T., Scatton, O., & Rebollo, A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101631 · Cited by 13
The N-terminal Set-β Protein Isoform Induces Neuronal Death
Trakhtenberg, E. F., Morkin, M. I., Patel, K. H., Fernandez, S. G., Sang, A., Shaw, P. X., Liu, X., Wang, Y., Mlacker, G. M., Gao, H., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.633883 · Cited by 12
Self-citation
Ligands for Ser/Thr phosphoprotein phosphatases: a patent review (2005-2015)
Lajarín-Cuesta, R., Arribas, R. L., & Rı́os, C. D. L. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2016.1135903 · Cited by 13
The zebrafish homologs of SET/I2PP2A oncoprotein: expression patterns and insights into their physiological roles during development
Serifi, I., Tzima, E., Soupsana, K., Karetsou, Z., Beis, D., & Papamarcaki, T. (2016) · Biochemical Journal · doi:10.1042/bcj20160523 · Cited by 12
Expression of Phosphorylated BRD4 Is Markedly Associated with the Activation Status of the PP2A Pathway and Shows a Strong Prognostic Value in Triple Negative Breast Cancer Patients
Sanz-Álvarez, M., Cristóbal, I., Luque, M., Santos, A., Zazo, S., Madoz‐Gúrpide, J., Caramés, C., Chiang, C., García‐Foncillas, J., Eroles, P., et al. (2021) · Cancers · doi:10.3390/cancers13061246 · Cited by 13
Antagonizing SET Augments the Effects of Radiation Therapy in Hepatocellular Carcinoma through Reactivation of PP2A-Mediated Akt Downregulation
Huang, C., Hung, M., Shih, C.-T., Hsieh, F., Kuo, C.-W., Tsai, M.-H., Chang, S.-S., Hsiao, Y., Chen, L., Chao, T., et al. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.249102 · Cited by 12
The one-two punch: Combination treatment in chronic myeloid leukemia
Sweet, K. L., Hazlehurst, L., & Pinilla-Ibarz, J. A. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.07.017 · Cited by 11
Disclosing the Interactome of Leukemogenic NUP98-HOXA9 and SET-NUP214 Fusion Proteins Using a Proteomic Approach
Mendes, A., Jühlen, R., Bousbata, S., & Fahrenkrog, B. (2020) · Cells · doi:10.3390/cells9071666 · Cited by 11
PPP2CA Is a Novel Therapeutic Target in Neuroblastoma Cells That Can Be Activated by the SET Inhibitor OP449
Galiger, C., Dahlhaus, M., Vitek, M. P., Debatin, K., & Beltinger, C. P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.744984 · Cited by 11
Self-citation
SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML
Mambro, A. D., Arroyo-Berdugo, Y., Fioretti, T., Randles, M. J., Cozzuto, L., Rajeeve, V., Cevenini, A., Austin, M. J., Esposito, G., Ponomarenko, J. V., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02840-1 · Cited by 9
SET Oncogene is Upregulated in Pediatric Acute Lymphoblastic Leukemia
Ekmekçi, S. S., Ekmekçi, C. G., Kandilci, A., Güleç, Ç., Akbıyık, M., Emrence, Z., Abacı, N., Karakaş, Z., Ağaoğlu, L., Ünüvar, A., et al. (2012) · Tumori Journal · doi:10.1177/030089161209800212 · Cited by 10
SET /I2 PP 2A overexpression induces phenotypic, molecular, and metabolic alterations in an oral keratinocyte cell line
Sobral, L. M., Coletta, R. D., Alberici, L. C., Curti, C., & Leopoldino, A. M. (2017) · FEBS Journal · doi:10.1111/febs.14148 · Cited by 10
New Cytotoxic Cerebrosides from the Red Sea Cucumber Holothuria spinifera Supported by In-Silico Studies
Abdelhameed, R. F. A., Eltamany, E. E., Hal, D. M., Ibrahim, A. K., AboulMagd, A. M., Al-Warhi, T. I., Youssif, K. A., El-kader, A. M. A., Hassanean, H. A.-H., Fayez, S., et al. (2020) · Marine Drugs · doi:10.3390/md18080405 · Cited by 10
A direct interaction between RhoGDIα/Tau alleviates hyperphosphorylation of Tau in Alzheimer's disease and vascular dementia
Zhang, H., Lü, F., Liu, P., Qiu, Z., Li, J., Wang, X., Xu, H., Zhao, Y., Li, X., Wang, H., et al. (2022) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-021-10049-w · Cited by 11
Second-Generation JK-206 Targets the Oncogenic Signal Mediator RHOA in Gastric Cancer
Beak, M., Park, S., Kim, J., Eom, H. J., Lee, H., Kim, Y. H., Lee, J., & Nam, S. (2022) · Cancers · doi:10.3390/cancers14071604 · Cited by 10
PP2A regulates signaling through hormonal receptors in breast cancer with important therapeutic implications
Cristóbal, I., Torrejón, B., Martínez‐Useros, J., Madoz‐Gúrpide, J., Rojo, F., & García‐Foncillas, J. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.08.005 · Cited by 10
The repression of oncoprotein SET by the tumor suppressor p53 reveals a p53-SET-PP2A feedback loop for cancer therapy
Yao, H., Xu, W., Liu, Y., Cao, Z., Wen, J., Zhang, M., Wu, Z., Yan, X., Jiao, Z., Zhang, Z., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-021-2123-8 · Cited by 9
The Effects of Protein Phosphatase 2A Activation with Novel Tricyclic Sulfonamides on Hepatoblastoma
Bownes, L. V., Julson, J. R., Quinn, C. H., Hutchins, S. C., Erwin, M. H., Markert, H. R., Stewart, J. E., Mroczek‐Musulman, E., Aye, J. M., Yoon, K. J., et al. (2023) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2023.02.017 · Cited by 9
Targeting PP2A in cancer: an underrated option
Sarais, F., Krempien, F., Koehn, C., Brewing, L., Classen, C. F., Walter, M., & Shokraie, O. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03560-y · Cited by 8
The SET oncoprotein promotes estrogen-induced transcription by facilitating establishment of active chromatin
Guo, C., Meza‐Sosa, K. F., Valle‐García, D., Zhao, G., Gao, K., Yu, L., Zhang, H., Chen, Y., Sun, L., Rockowitz, S., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2206878120 · Cited by 9
PP2A is activated by cytochrome c upon formation of a diffuse encounter complex with SET/TAF-Iβ
Casado‐Combreras, M. Á., Rivero-Rodríguez, F., Elena‐Real, C. A., Molodenskiy, D. S., Dı́az-Quintana, A., Martinho, M., Gerbaud, G., González‐Arzola, K., Velázquez‐Campoy, A., Svergun, D. I., et al. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.07.009 · Cited by 7
SET mediates TCE-induced liver cell apoptosis through dephosphorylation and upregulation of nucleolin
Ren, X., Huang, X., Yang, X., Liu, Y., Liu, W., Huang, H., Wu, D., Zou, F., & Liu, J. (2017) · Oncotarget · doi:10.18632/oncotarget.16785 · Cited by 7
Potential roles of PP2A-Rac1 signaling axis in pancreatic β-cell dysfunction under metabolic stress: Progress and promise
Kowluru, A. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114138 · Cited by 7
Apolipoprotein-mimetic Peptides: Current and Future Prospectives
Pande, A. H., Nankar, S. A., Ahmed, S., & Sharma, S. S. (2022) · Current Protein and Peptide Science · doi:10.2174/1389203723666221003122624 · Cited by 6
Biomarkers and Target-Specific Small-Molecule Drugs in Alzheimer’s Diagnostic and Therapeutic Research: From Amyloidosis to Tauopathy
Li, S., & Bhalla, R. (2024) · Neurochemical Research · doi:10.1007/s11064-024-04178-w · Cited by 8
SET levels contribute to cohesion fatigue
Yang, L., Zhang, Q., Niu, T., & Liu, H. (2021) · Molecular Biology of the Cell · doi:10.1091/mbc.e20-12-0778 · Cited by 6
Deregulation of protein phosphatase 2A inhibitor SET is associated with malignant progression in breast cancer
Tozuka, K., Wongsirisin, P., Nagai, S. E., Kobayashi, Y., Kanno, M., Kubo, K., Takai, K., Inoue, K., Matsumoto, H., Shimizu, Y., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-93620-y · Cited by 6
Protein Phosphatase 2A as a Therapeutic Target in Pulmonary Diseases
Yu, H. K. Y., Zaveri, S., Sattar, Z., Schaible, M., Gandara, B. P., Uddin, A., McGarvey, L. R., Ohlmeyer, M. H. J., & Geraghty, P. M. (2023) · Medicina · doi:10.3390/medicina59091552 · Cited by 5
A Novel Interaction of the Catalytic Subunit of Protein Phosphatase 2A with the Adaptor Protein CIN85 Suppresses Phosphatase Activity and Facilitates Platelet Outside-in αIIbβ3 Integrin Signaling
Khatlani, T., Pradhan, S., Da, Q., Shaw, T. S., Buchman, V. L., Crúz, M. A., & Vijayan, K. V. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.704296 · Cited by 5
Assembly and remodeling of viral DNA and RNA replicons regulated by cellular molecular chaperones
Sekiya, T., Hu, Y., Kato, K., Okuwaki, M., Kawaguchi, A., & Nagata, K. (2017) · Biophysical Reviews · doi:10.1007/s12551-017-0333-z · Cited by 5
Targeting of SET/I2PP2A oncoprotein inhibits Gli1 transcription revealing a new modulator of Hedgehog signaling
Serifi, I., Besta, S., Karetsou, Z., Giardoglou, P., Beis, D., Niewiadomski, P., & Papamarcaki, T. (2021) · Scientific Reports · doi:10.1038/s41598-021-93440-0 · Cited by 5
Oncoprotein SET dynamically regulates cellular stress response through nucleocytoplasmic transport in breast cancer
Zhao, G., Zhang, H., Zhang, Y., Zhao, N., Mao, J., Shang, P., Gao, K., Meng, Y., Tao, Y., Wang, A., et al. (2022) · Cell Biology and Toxicology · doi:10.1007/s10565-022-09784-4 · Cited by 4
Merkel Cell Polyomavirus targets SET/PP2A complex to promote cellular proliferation and migration
Gupta, P., Venuti, A., Savoldy, M. A., Harold, A., Zito, F. A., Taverniti, V., Romero-Medina, M. C., Galati, L., Sirand, C., Shahzad, N., et al. (2024) · Virology · doi:10.1016/j.virol.2024.110143 · Cited by 3
HDACI regulates the PI3K/Akt signaling pathway to reverse MCF-7/PTX resistance by inhibiting SET
Zhang, W., Zheng, X., Meng, T., You, H., Dong, Y., Xing, J., & Chen, S. (2016) · RSC Advances · doi:10.1039/c6ra06423j · Cited by 3
Endogenous inhibitors of PP2A activate oncogenic and DNA damage response kinases in glioblastoma
Jacob, J., Nimjee, S. M., Elder, J. B., Chakravarti, A., & Palanichamy, K. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218325 · Cited by 2
Synthesis and anticancer profile of novel FTY720 analogues with azobenzene frameworks
Fazekašová, S., Gonda, J., Martinková, M., Pilátová, M. B., Majirská, M., Turčanová, V., & Jáger, D. (2023) · Tetrahedron · doi:10.1016/j.tet.2023.133391 · Cited by 2
Silencing of the human SET gene in vitro with lentivirus-mediated RNA interference
LIU, Y., He, P., Zhang, M., Shi, L., Zhu, H., Wang, Y., & Zhao, J. (2013) · Molecular Medicine Reports · doi:10.3892/mmr.2013.1275 · Cited by 2
Non-canonical transcriptional regulation of INHAT subunit SET/TAF-Iβ by EZH2
Hwang, I. J., Park, J., & Seo, S. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.10.041 · Cited by 2
SET knockdown attenuated phenotype modulation and calcium channel associated markers of airway smooth muscle cells in asthmatic mice
Li, J., He, Q., Wang, L., Chen, D., Qiu, C., Xu, P., Lu, Y., Zeng, Y., & Chen, R. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-573 · Cited by 2
H2AX phosphorylation driven by the SET-PP2A axis maintains glioma stem cell properties
Han, C., Li, N., Banerjee, A. T., Wang, L., Yang, Y., Zhong, Y., Wu, S., Manring, H. R., Zhang, N., Showalter, C. A., et al. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101961 · Cited by 1
Anticancer agent FTY720 upregulates cell cycle regulator BTG2 via the SET/TAF-Iβ –PP2A–SMAD3 signaling pathway and induces G2/M arrest in leukemia
Park, J., Kim, Y., Park, H., Yun, G., & Seo, S. (2026) · Genes & Genomics · doi:10.1007/s13258-026-01739-x · Cited by 1
HNSCC Biomarkers Derived from Key Processes of Cancerogenesis
Raudenská, M., Gumulec, J., Fribley, A. M., & Masařík, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-27647-2_7 · Cited by 1
Development and identification of Set transgenic mice
Xu, S., Liu, X., Gao, L., Xu, B., Li, J., Gao, C., Cui, Y., & Liu, J. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.5612 · Cited by 1
Date and Place of Birth
Shandler, J. (2020) · Oxford University Press eBooks · doi:10.1093/oso/9780190651961.003.0002 · Cited by 1
SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML.Preprint
Mambro, A. D., Arroyo-Berdugo, Y., Fioretti, T., Randles, M. J., Cozzuto, L., Rajeeve, V., Cevenini, A., Austin, M. J., Esposito, G., Ponomarenko, J. V., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2583091/v1 · Cited by 1
Tamoxifen resistance in breast cancer : a proteomic approach
Phillips, E. (2012) · University of Birmingham Institutional Research Archive (University of Birmingham)
Ready, set? Go! Microscopy and image analysis of cell signalling in cell migration
Lam, B. D. (2013) · UvA-DARE (University of Amsterdam)
Characterization of aberrant c-Myc phosphorylation and stability in acute myeloid and lymphoblastic leukemia
Tibbitts, D. (2014) · doi:10.6083/m45b00fn
The immunosuppressant FTY720 (Fingolimod) induces nuclear exit of the proto-oncogene SET/I2PP2A
Lam, B. D., Anthony, E. C., & Hordijk, P. L. (2013) · Pure Amsterdam UMC · doi:10.4255/mcpharmacol.13.10
Análise da proteína hnRNP K nas linhagens celulares NB4 e NB4-R2 de leucemia promielocítica aguda com ênfase na patogênese e na diferenciação celular pelo ácido all-trans retinoico
Padovani, K. S. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.60.2017.tde-23052017-142507
Estudo in vitro e in vivo de novos compostos: com alvo-específico (hnRNP K e SET) ou com ação na mitocôndria para uso como antitumoral em carcinoma oral ou como citoprotetor em célula não-tumoral
Goto, R. N. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.60.2017.tde-23112017-161303
Investigation of approaches for overcoming chemoresistance in pancreatic cancer
Hung, S. W. (2014)
Análise dos mecanismos antitumorais de FTY720 em linhagens humanas de carcinoma espinocelular de cabeça e pescoço
dos Santos, L. F. (2019) · doi:10.11606/t.60.2019.tde-23052019-084333
The Key Role of the Phosphatase PP2A in the Development of Acute Myeloid Leukemia
Marco, J., Peris, I., Vicente, C., & Arriazu, E. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.94380
Faculty Opinions recommendation of Selective PP2A Enhancement through Biased Heterotrimer Stabilization.
Yu, E. W. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737780632.793574081
Supplementary Figure Legends from Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia
Agarwal, A., MacKenzie, R. J., Pippa, R., Eide, C. A., Oddo, J., Tyner, J. W., Sears, R. C., Vitek, M. P., Odero, M. D., Christensen, D. J., et al. (2023) · doi:10.1158/1078-0432.22449384
Self-citation
Supplementary Figure Legends from Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia
Agarwal, A., MacKenzie, R. J., Pippa, R., Eide, C. A., Oddo, J., Tyner, J. W., Sears, R. C., Vitek, M. P., Odero, M. D., Christensen, D. J., et al. (2023) · doi:10.1158/1078-0432.22449384.v1
Self-citation
Antitumoral Effect on Liver Cancer of a Tumor-Penetrating and Interfering Peptide
Savier, É., Tufféry, P., Bruzoni-Giovannelli, H., Boudjelloul, R., & Rebollo, A. (2025) · Methods in pharmacology and toxicology · doi:10.1007/978-1-0716-4374-7_2
Evolutionary Pro‐To‐Thr Mutation in the Intrinsically Disordered Domain of ANP32 Family Members Modulates Their Target Binding Modes
Baños‐Jaime, B., Uceda, A. B., Rivero‐Rodríguez, F., Casado‐Combreras, M. Á., Velázquez‐Cruz, A., Velázquez‐Campoy, A., Corrales‐Guerrero, L., la Rosa, M. Á. D., & Díaz‐Moreno, I. (2025) · Advanced Science · doi:10.1002/advs.202415566
Therapeutic Use of ApoE-Mimetic Peptides
Ahmed, S., Pande, A. H., & Sharma, S. S. (2025) · Springer eBooks · doi:10.1007/978-3-031-52641-1_43-1
Targeting SET to counteract Lyn activation demonstrates anti-cancer potential in diffuse large B-cell lymphoma
Chen, J.-L., Chu, P., Huang, C.-T., Wang, W., Chang, Y.-Y., Dai, M., & Liu, C. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01874-x
Chromatin structure and DNA repair
Hoffbeck, A.-S. (2013) · theses.fr (ABES) · doi:10.70675/ab1412f8zbddbz4ed2z8999zbb37db7c920a
Cell penetrating and interfering peptides as new cancer therapy
Zhang, X. (2017) · theses.fr (ABES) · doi:10.70675/b2053021ze747z4f1azacb7z8a87a14ec9e3
Intérêt des peptides bi-fonctionnels dans le traitement des cancers. Application au carcinome hépatocellulaire
Savier, É. (2023) · theses.fr (ABES) · doi:10.70675/78863fc0z6809z4b50z97acz3156425d1052
BindingDB Entry 50018255: Strategies for Targeting Serine/Threonine Protein Phosphatases with Small Molecules in Cancer.
BindingDB (2024) · UC San Diego · doi:10.7270/q2wd44rv

Authors: Switzer, C. H., Cheng, R. Y. S., Vitek, T. M., Christensen, D. J., Wink, D. A., & Vitek, M. P.
Affiliations: National Institutes of Health (US)
Cognosci (United States) (US)
Duke Medical Center (US)
Corresponding author: Wink, D A
Vitek, M P
ORCID: Switzer, C H
Cheng, R Y S
Christensen, D J
Wink, D A
Vitek, M P
Venue: Oncogene
Publisher: Springer Science and Business Media LLC
Published: 2011-02-07
Volume: 30
Issue: 22
Pages: 2504-2513
ISSN: 0950-9232 (ISSN-L)
1476-5594
DOI: 10.1038/onc.2010.622
PMC: PMC3107340
OpenAlex: W2021359328
Cited by: 171
References: 50
Citations by year: 2026: 2 · 2025: 6 · 2024: 3 · 2023: 11 · 2022: 12 · 2021: 12 · 2020: 9 · 2019: 10 · 2018: 11 · 2017: 16 · 2016: 15 · 2015: 14 · 2014: 15 · 2013: 14 · 2012: 15
FWCI: 6.49
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Oncogene (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health
National Cancer Institute (ZIASC007281, ZIABC010899)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Keywords: protein phosphatase 2A, nm23-H1, Akt signaling, cell proliferation, cell migration and invasion, Rac1, glioblastoma, breast adenocarcinoma, metastasis suppressor, tumor suppressor gene reactivation, cancer therapy targets
MeSH terms: Antineoplastic Agents, Cell Movement, DNA-Binding Proteins, Humans, Neoplasms, Peptides, Transcription Factors, Signal Transduction, rac1 GTP-Binding Protein, Cell Line, Tumor, Cell Proliferation, Proto-Oncogene Proteins c-akt, NM23 Nucleoside Diphosphate Kinases, Histone Chaperones

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeting SET/I2PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks